- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03781232
Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes
Non-invasive Glucose Measurement With Raman Technology. Calibration of Newly Developed Devices in Patients With Type 1 and Type 2 Diabetes - Glucobrunn Study
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Subjects are recruited at two different sites.
Site 1: In group 1 subjects will on their regular stay in the clinic perform four measurement sessions a day. A measurement session consist of a reference capillary blood sample and two measures on the IMD.
Site 2: The study in group 2 consists of 26 home-based measurements and two in-clinic days. During the home measurements, 6 measurement sessions will be performed by the subjects a day. A measurement session consists of two reference BGMs, two reference CGMs and two measurements on the device. On in-clinic visits, subjects will be administered high glucose breakfast and the following 6-7 hours, measurement sessions are performed every 15 minutes.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Bad Heilbrunn, Alemanha, 83670
- m&i-Fachklinik Bad Heilbrunn - Zentrum für Diabetes und Stoffwechselerkrankungen
-
Ulm, Alemanha, 89081
- Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- At least 18 years of age
- Have a diagnosis of type 1 or type 2 diabetes mellitus (for RSP-09-02, only patients with type 1 diabetes)
- Skin phototype 1-4
- Be willing to perform a minimum of 6 / 12 (31 during excursion days) finger sticks per day during the study
- Be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol
- Be willing to provide written signed and dated informed consent
Exclusion Criteria:
- Inability to comply with the study procedures as described by the study protocol, according to the opinion of the investigator, due to e.g. known psychiatric diagnoses, lack of cognitive ability, alcohol dependency, drug use, psychosocial overload
- Have known severe allergy to medical grade adhesive or isopropyl alcohol used to clean the skin
- Be breastfeeding, pregnant, attempting to conceive or not willing and able to practice birth control during the study execution (applicable to female subjects only)
- Unable to hold hand/arm steadily (including tremors and Parkinson's Disease)
- Severe diabetes related complications such as advanced autonomic neuropathy, kidney disease, foot ulcers, legal blindness, or symptomatic cardiovascular disease as evidenced by a history of cardiovascular episode(s)
- Systemic or topical administration of glucocorticoids for the past 7 days
- Undergoing dialysis treatment
- Have extensive skin changes/diseases at the proposed measurement site (thenar) that could interfere with the accuracy of interstitial glucose measurements
- Have a concomitant medical condition which could interfere with the study devices (study arm 1: intake of acetaminophen study arm 2: intake of salicylic acid or higher doses of ascorbic acid)
- Unsuitable for participation due to any other cause as determined by the Investigator. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation e.g. with required documentation
- Dependency from the sponsor or the clinical investigator (e.g. co-workers of the sponsor, the study site, and/ or their families)
Additional exclusion criteria for study arm 2:
- Severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment
- Hypoglycemia unawareness
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: RSP-09-01
Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic.
A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
|
Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
|
Experimental: RSP-09-02
Enrolled subjects will measure at home for 26 six days and visit the clinic two times.
During home measurements, 6 measurement sessions will be performed by the subject a day.
A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3.
On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
|
Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Generation and validation of predictive models by Inter Subject Unified Performance (ISUP).
Prazo: 2 years
|
Spectral Raman data will be collected together with paired reference measurements. Collected data will be used to generate calibration models capable of predicting tissue glucose levels. Models will be validated on independent data sets using the ISUP measure. |
2 years
|
Generation and validation of predictive models by Mean Absolute Relative Difference (MARD) measures
Prazo: 2 years
|
Spectral Raman data will be collected together with paired reference measurements. Collected data will be used to generate calibration models capable of predicting tissue glucose levels. Models will be validated on independent data sets using the MARD measure. |
2 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Guido Freckmann, Dr., Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- RSP-09
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Prototype 0.3
-
Teva Branded Pharmaceutical Products R&D, Inc.ConcluídoEsclerose Múltipla Remitente Recorrente
-
Universitaire Ziekenhuizen KU LeuvenRescindido
-
ANRS, Emerging Infectious DiseasesRecrutamento
-
Dokuz Eylul UniversityConcluído